Logo for Evaxion Biotech A/S

Evaxion Biotech Investor Relations Material

Latest events

Logo for Evaxion Biotech A/S

Q3 2024

Evaxion Biotech
Logo for Evaxion Biotech

Q3 2024

31 Oct, 2024
Logo for Evaxion Biotech

Investor Update

27 Sep, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Evaxion Biotech A/S

Access all reports
Evaxion Biotech utilizes the AI platform, which is designed to reduce the identification of novel epitopes, and to develop neoantigens, vaccines, and antibody-based therapies; pNLS platform that is designed to identify novel protein structures through computational design; and 2D-to-3D structural similarity searching algorithm. It is developing EB023, a peptide based immunotherapy for the treatment of head and neck cancer. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.